IIT2025-03-YANG-LIFT-HCC

Inclusion criteria

• ✓. Age ≥ 18 at the time of signing the Informed Consent Form.
• ✓. Beyond UCSF criteria HCC with diagnosis confirmed histologically/cytologically, radiologically, or clinically per AASLD criteria, with life expectancy of at least 12 months.
• ✓. Histologically confirmed HCC via liver biopsy obtained within 3 months prior to initiation of study treatment as part of SOC. If no historical biopsy is available, a biopsy must be performed at screening for confirmation. Screening liver biopsy may be conducted as part of research activities if not performed per SOC practice.
• ✓. ECOG performance status ≤ 2 within 7 days prior to initiation of study treatment.
• ✓. HCC with Measurable disease by mRECIST (see Appendix 11.2) (at least one ≥10mm target lesion) that is not suitable for resection per standard clinical practice and beyond UCSF criteria (see section 11.5) confirmed with most recent imaging obtained within 3 months prior to screening.
• ✓. For subjects of childbearing potential (SOCBP), negative serum or urine pregnancy test and agreement to use adequate contraception or abstinence from the time of screening until 3 months following the last dose of Durvalumab.
• ✓. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.